Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus

被引:0
作者
Yong, Patrick F. K. [1 ]
Annals, Rachel [2 ]
Diwakar, Lavanya [3 ]
Elkhalifa, Shuayb [4 ]
Gompels, Mark [5 ]
Jain, Rashmi [6 ]
Karim, Mohammed Yousuf [7 ]
Khan, Sujoy [8 ]
Metcalfe, Angela [2 ]
Noorani, Sadia [9 ]
Steele, Cathal [10 ]
Kiani-Alikhan, Sorena [11 ]
Garcez, Tomaz [12 ]
机构
[1] Frimley Hlth NHS Fdn Trust, Dept Immunol, Frimley, England
[2] Hereditary Angioedema UK, Bridgwater, England
[3] Univ Hosp North Midlands NHS Trust, Dept Immunol, Stoke On Trent, England
[4] Cleveland Clin Abu Dhabi, Dept Allergy & Immunol, Abu Dhabi, U Arab Emirates
[5] North Bristol NHS Trust, Dept Immunol, Bristol, England
[6] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Immunol, Oxford, England
[7] Sidra Med, Hematopatho, Doha, Qatar
[8] Hull Univ Teaching Hosp NHS Trust, Dept Immunol & Allergy, Kingston Upon Hull, England
[9] Sandwell & West Birmingham NHS Trust, Dept Immunol, Birmingham, England
[10] Royal Hosp Belfast, Reg Immunol Serv, Belfast, North Ireland
[11] Royal Free London NHS Fdn Trust, Dept Immunol, London, England
[12] Manchester Univ NHS Fdn Trust, Dept Immunol, Manchester, England
关键词
hereditary angioedema; HAE; C1 inhibitor deficiency; prophylaxis; Delphi consensus; C1 INHIBITOR DEFICIENCY;
D O I
10.1093/cei/uxae020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hereditary angioedema (HAE) is a rare inherited disorder causing recurrent episodes of swelling that can be potentially life threatening. Treatment of HAE can be divided into on-demand treatment for swelling, and prophylaxis. The last UK consensus on HAE was in 2014 and since then, new medications for prophylaxis have been developed, with more drugs in the pipeline. International guidelines currently recommend the use of long-term prophylaxis (LTP) as the only way of achieving disease control and normalizing patient lives. Modern prophylactic medications are available in the UK, although access is restricted primarily by HAE attack frequency. To establish an updated view of UK clinicians and patients, a Delphi process was used to develop statements regarding LTP as well as other aspects of HAE management. There was consensus that UK access criteria for modern LTP agents based on numerical frequency of attacks alone are too simplistic and potentially disadvantage a cohort of patients who may benefit from LTP. Additionally, there was agreement that patients should be seen in expert centres, remote monitoring of patients is popular post-pandemic, and that the use of patient-reported outcome measures has the potential to improve patient care. Psychological health is an area in which patients may benefit, and recognition of this is important for future research and development. To establish an updated view of UK clinicians and patients, a Delphi process was used to develop statements regarding long-term prophylaxis and other aspects of hereditary angioedema management. UK access criteria for modern LTP agents based on numerical frequency of attacks alone were thought to be too simplistic, and potentially disadvantage a cohort of patients who may benefit from LTP. There was agreement that patients should be seen in expert centres, remote monitoring of patients is popular post-pandemic, patient-reported outcome measures has the potential to improve patient care, and psychological support may benefit patients.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 50 条
[41]   Management of hereditary angioedema in resource-constrained settings: A consensus statement from Indian subcontinent [J].
Jindal, Ankur Kumar ;
Sil, Archan ;
Aggarwal, Ridhima ;
Vinay, Keshavamurthy ;
Bishnoi, Anuradha ;
Suri, Deepti ;
Rawat, Amit ;
Kumaran, Muthu Sendhil ;
Saikia, Biman ;
Sarkar, Rashmi ;
Gupta, Lalit ;
Kumar, D. Dinesh ;
Jindal, Rashmi ;
Sukumaran, T. U. ;
Ouseph, Jose ;
Longhurst, Hilary ;
Pawankar, Ruby ;
Singh, Surjit ;
Dogra, Sunil .
ASIA PACIFIC ALLERGY, 2023, 13 (02) :60-65
[42]   Review of Recent Guidelines and Consensus Statements on Hereditary Angioedema Therapy with Focus on Self-Administration [J].
Cicardi, M. ;
Craig, T. J. ;
Martinez-Saguer, I. ;
Hebert, J. ;
Longhurst, H. J. .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2013, 161 :3-9
[43]   Lanadelumab for the treatment of hereditary angioedema [J].
Wu, Maddalena Alessandra .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (12) :1233-1245
[44]   TREATMENT OF LARYNGEAL HEREDITARY ANGIOEDEMA [J].
Richman, Mark J. ;
Talan, David A. ;
Lumry, William R. .
JOURNAL OF EMERGENCY MEDICINE, 2012, 42 (01) :44-47
[45]   Hereditary angioedema in children and adolescents [J].
Mansour, Eli ;
Veronez, Camila L. ;
Craig, Timothy ;
Grumach, Anete Sevciovic .
ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2022, 50 :1-6
[46]   Hereditary Angioedema: Implications of Management [J].
Pathria, Mohini ;
Krishnaswamy, Guha ;
Guarderas, Juan C. .
SOUTHERN MEDICAL JOURNAL, 2017, 110 (02) :101-106
[47]   Hereditary angioedema: A therapeutic revolution [J].
Bouillet, L. .
REVUE DE MEDECINE INTERNE, 2012, 33 (03) :150-154
[48]   Hereditary Angioedema Management: Individualization [J].
Epland, Kristin ;
Wayne, Melanie ;
Pein, Heather .
JNP-JOURNAL FOR NURSE PRACTITIONERS, 2021, 17 (10) :1199-1203
[49]   Prophylactic Therapy for Hereditary Angioedema [J].
Longhurst, Hilary ;
Zinser, Emily .
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2017, 37 (03) :557-+
[50]   Hereditary angioedema: a Chinese perspective [J].
Liu, Shuang ;
Xu, Yingyang ;
Liu, Yaping ;
Zhi, Yuxiang .
EUROPEAN JOURNAL OF DERMATOLOGY, 2019, 29 (01) :14-20